Aims When it occurs, pulmonary vein (PV) stenosis after atrial fibrillation (AF) ablation is
associated with significant morbidity. Even mild-to-moderate PV narrowing may have long …

A significant proportion of patients who suffer from atrial fibrillation (AF) and are in need of
thromboembolic protection are not treated with oral anticoagulation or discontinue this …

(1) Background: Atrial fibrillation (AF) is a major risk factor for stroke and is often
underdiagnosed, despite being present in 13–26% of ischemic stroke patients. Recently, a …

The identification of the pulmonary veins as a trigger source for atrial fibrillation (AF) has
established pulmonary vein isolation (PVI) as a key target for AF ablation. However, PVI …

Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial
fibrillation. Due to advances in pharmacotherapy the anticoagulants used for this purpose …

Clinical outcomes of catheter ablation for atrial fibrillation (AF) are suboptimal due, in part, to
challenges in achieving durable lesions. Although focal point-by-point ablation allows for the …

Availability of devices capable of continuous rhythm monitoring such as smartwatches,
implantable loop recorders, or pacemakers/defibrillators is continuously increasing …

The limited literature and increasing interest in studies on cardiac electrophysiology,
explicitly focusing on cardiac ion channelopathies and sudden cardiac death in diverse …

Aims Atrial fibrillation/atrial flutter (AF/AFL) remains a significant public health concern on a
global scale, with metabolic risks playing an increasingly prominent role. This study aimed to …

Introduction Balancing antithrombotic therapy for atrial fibrillation (AF) patients undergoing
percutaneous coronary intervention (PCI) remains a clinical challenge due to coexisting …